Several THR-β agonists with oral bioavailability and liver-targeted properties have been developed and showed preclinical efficacy in NAFLD and nonalcoholic steatohepatitis (NASH) models [21–26]. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.